Search

everythinglearnresearchcommunity

for

Search:↓

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Blocking IL-17 signaling may reduce skin inflammation and delay aging.

S100A7 and IL-17 may contribute to inflammation in lichen planopilaris.

Blocking IL-17a can improve age-related smell loss in mice.

Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

Terbinafine effectively treated kerion celsi despite disrupted immune responses.

Higher IL-17A levels indicate more severe alopecia areata.

Targeting IL-17 could help treat pattern hair loss.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Mesenchymal stem cells in people with Hidradenitis Suppurativa are more inflammatory, possibly contributing to the disease.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

Hair follicles play a crucial role in regulating skin barrier function.

DHT inhibition may increase spinal bone growth in ankylosing spondylitis.

A medication may help with hair growth in psoriasis, and a skin condition might be linked to a specific bacteria.

Secukinumab for psoriasis may cause hair loss.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Two patients with psoriasis grew extra hair after using certain psoriasis medications.

Certain gene variations are linked to alopecia areata.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

Bimekizumab can improve scarring alopecia in severe psoriasis.

Bimekizumab effectively treated a man's chronic beard hair loss.

Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.

Secukinumab can cause hair loss, which may improve after stopping the medication.